On Tuesday, Neogenomics Inc (NASDAQ: NEO) was 3.75% up from the session before settling in for the closing price of $16.53. A 52-week range for NEO has been $12.77 – $20.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 17.35% over the past five years. When this article was written, the company’s average yearly earnings per share was at 181.67%. With a float of $126.84 million, this company’s outstanding shares have now reached $128.06 million.
Let’s look at the performance matrix of the company that is accounted for 2100 employees. In terms of profitability, gross margin is 42.47%, operating margin of -13.71%, and the pretax margin is -12.39%.
Neogenomics Inc (NEO) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Neogenomics Inc stocks. The insider ownership of Neogenomics Inc is 1.19%, while institutional ownership is 97.50%. The most recent insider transaction that took place on Nov 15 ’24, was worth 79,475. In this transaction General Counsel of this company sold 5,175 shares at a rate of $15.36, taking the stock ownership to the 37,129 shares. Before that another transaction happened on Nov 15 ’24, when Company’s Officer proposed sale 5,175 for $15.79, making the entire transaction worth $81,713.
Neogenomics Inc (NEO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 181.67% per share during the next fiscal year.
Neogenomics Inc (NASDAQ: NEO) Trading Performance Indicators
You can see what Neogenomics Inc (NEO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.62, a number that is poised to hit 0.03 in the next quarter and is forecasted to reach 0.20 in one year’s time.
Technical Analysis of Neogenomics Inc (NEO)
Neogenomics Inc (NASDAQ: NEO) saw its 5-day average volume 1.16 million, a positive change from its year-to-date volume of 0.81 million. As of the previous 9 days, the stock’s Stochastic %D was 21.58%. Additionally, its Average True Range was 0.70.
During the past 100 days, Neogenomics Inc’s (NEO) raw stochastic average was set at 70.30%, which indicates a significant increase from 34.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.48% in the past 14 days, which was higher than the 43.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.78, while its 200-day Moving Average is $15.09. Nevertheless, the first resistance level for the watch stands at $17.45 in the near term. At $17.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $18.33. If the price goes on to break the first support level at $16.57, it is likely to go to the next support level at $15.99. Assuming the price breaks the second support level, the third support level stands at $15.70.
Neogenomics Inc (NASDAQ: NEO) Key Stats
There are 128,361K outstanding shares of the company, which has a market capitalization of 2.20 billion. As of now, sales total 591,640 K while income totals -87,970 K. Its latest quarter income was 167,820 K while its last quarter net income were -17,700 K.
